Respiratorius
  • Home
  • About us
    • About us
    • History
    • Board of Directors and CEO
  • R and D
    • R and D
    • Scientific Publications
  • Investors
    • Investerare (SV)
    • Investors
    • Press releases
    • Financial Reports
  • News
  • Contact
  • Search
  • Menu Menu

K Drott, M.D/Phd, Associate professor: VAL001 – Clinical Results & Medical Perspectives

24 January 2019
Read more
https://www.respiratorius.com/wp-content/uploads/2019/09/KD-e1716880848925.jpg 923 923 Malin Bergholm https://www.respiratorius.com/wp-content/uploads/2019/09/Respiratorius_logo-300x57.png Malin Bergholm2019-01-24 18:16:352023-02-15 09:33:15K Drott, M.D/Phd, Associate professor: VAL001 – Clinical Results & Medical Perspectives

A. Mansson, Non-Executive Director, Respiratorius: VAL001 – Business Opportunity Summary

1 January 2019
Read more
https://www.respiratorius.com/wp-content/uploads/2019/09/AM.jpg 1039 1041 Malin Bergholm https://www.respiratorius.com/wp-content/uploads/2019/09/Respiratorius_logo-300x57.png Malin Bergholm2019-01-01 13:39:032023-02-15 09:33:25A. Mansson, Non-Executive Director, Respiratorius: VAL001 – Business Opportunity Summary

ARCHIVE

  • “Fortsätter minska risken i projektet”, vd-intervju i BioStock
  • Positivt patentbesked och säkrad finansiell uthållighet
  • ”Finns intresse att delfinansiera fas III”
  • Fördjupade partnerdiskussioner för Respiratorius
  • Respiratorius vd kommenterar det andra kvartalet
  • Respiratorius fortsätter att stärka VAL001
  • Modell stärker Respiratorius projekt
  • Respiratorius fortsätter jakten på avtalspartner
  • Vd kommenterar händelserikt år
  • Respiratorius vd om de senaste resultaten
  • Redeyes Filip Einarsson har intervjuat Respiratorius VD Johan Drott
  • Positiva resultat från PK-studie
  • Fokus på bolagsuppdelning för Respiratorius under Q4
  • Vd-intervju om emission och avknoppning – mars 2022
  • Respiratorius – Aktiedagen Stockholm 15 mars 2022
  • Respiratorius får grönt ljus för PK-studie
  • Respiratorius har tagit flera kliv framåt i höst
  • Respiratorius blickar framåt mot en spännande höst
  • Respiratorius – Bolagspresentation på BioStock Live, 9 mars 2021
  • Respiratorius – Bolagspresentation på BioStock Live, 4 juni 2020
  • Respiratorius – Småbolagsdagen Stockholm den 10 juni 2020
  • BioStock VD-intervju, Respiratorius 2 juni, 2020 (Swedish)
  • Respiratorius: CEO Johan Drott presents at Growth Day 2020 (in Swedish)
  • Johan Drott, CEO presenterar på Life Science Day 2019 (Swedish)
  • Johan Drott CEO, presenterar på Redeye Investor Forum (Swedish)
  • Luftrörsvidgande effekt visad in vivo för nya substansen RES030-085 inom RESP9000
  • K Drott, M.D/Phd, Associate professor: VAL001 – Clinical Results & Medical Perspectives
  • A. Mansson, Non-Executive Director, Respiratorius: VAL001 – Business Opportunity Summary

Recent Posts

  • “Fortsätter minska risken i projektet”, vd-intervju i BioStock
  • Positivt patentbesked och säkrad finansiell uthållighet
  • ”Finns intresse att delfinansiera fas III”
  • Fördjupade partnerdiskussioner för Respiratorius
  • Respiratorius vd kommenterar det andra kvartalet

Recent Comments

    Archives

    • November 2024
    • August 2024
    • June 2024
    • February 2024
    • August 2023
    • July 2023
    • June 2023
    • May 2023
    • February 2023
    • November 2022
    • September 2022
    • May 2022
    • March 2022
    • January 2022
    • November 2021
    • June 2021
    • March 2021
    • June 2020
    • November 2019
    • September 2019
    • June 2019
    • January 2019
    • November 2018
    • November 2017

    Categories

    • (SV) Pressmeddelanden
    • News

    In Short

    Respiratorius AB (publ) develops candidate drugs with the goal of launching drugs to treat aggressive lymphoma (cancer).

    CONTACT

    Respiratorius AB
    Medicon Village

    Scheeletorget 1, 223 81 Lund, Sweden

    info@respiratorius.com
    +46 70 922 41 40

    PAGES

    • Home
    • About us
    • R and D
    • Investors
    • Press releases
    • News
    • Contact

    PRIVACY POLICY AND COOKIE POLICY

    Privacy policy for Respiratorius AB

    Cookie policy for Respiratorius AB

    Scroll to top
    Manage cookie consent

    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Alternativ
    Den tekniska lagringen eller åtkomsten är nödvändig för det legitima syftet att lagra inställningar som inte efterfrågas av abonnenten eller användaren.
    Statistics
    Den tekniska lagringen eller åtkomsten som används uteslutande för statistiska ändamål. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    he technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}